Qualigen Therapeutics Inc.
13F holders, Q1 2024 (March 31)20holders
2famous investors
$0.39avg. 13F price*
At the end of Q1 2024, 20 institutions reported holding Qualigen Therapeutics Inc. in their 13F filings. The largest holders were Citadel Advisors ($22K), Renaissance Technologies ($17K) and Geode Capital Management, LLC ($16K). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Qualigen Therapeutics Inc.
- CUSIP
- 74754R202
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $36K |
| Exits | 3 | $192 |
Ownership 20 holders
| Citadel Advisors | 0.00% | Add +64.4% | 57,176 | $22K |
| Renaissance Technologies | 0.00% | New | 42,972 | $17K |
| Geode Capital Management, LLC | 0.00% | No change | 41,895 | $16K |
| Virtu Financial LLC | 0.00% | New | 27,549 | $11K |
| BlackRock Inc. | 0.00% | Reduce -0.9% | 25,607 | $10K |
| Vanguard Group Inc. | 0.00% | No change | 22,827 | $9K |
| Northern Trust Corp. | 0.00% | No change | 11,919 | $5K |
| State Street Corp. | 0.00% | No change | 10,930 | $4K |
| XTX Topco Ltd | 0.00% | New | 10,853 | $4K |
| HRT Financial LP | 0.00% | New | 12,503 | $4K |
| HighMark Wealth Management LLC | 0.00% | No change | 8,009 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +15.7% | 6,087 | $2K |
| US Bancorp \de | 0.00% | No change | 824 | $330 |
| Group One Trading LLC | 0.00% | No change | 423 | $165 |
| Retirement Group, LLC | 0.00% | No change | 350 | $140 |
| JPMorgan Chase & Co. | 0.00% | Reduce -25.9% | 286 | $112 |
| Wells Fargo & Company | 0.00% | Add +5.1% | 41 | $16 |
| Archer Investment Corp | 0.00% | No change | 16 | $6 |
| Bank of America Corp. | 0.00% | Reduce -98.8% | 10 | $4 |
| Royal Bank of Canada | 0.00% | No change | 4 | $0 |
"% of holder's portfolio" is QUALIGEN THERAPEUTICS INC's weight in each manager's 13F, not the share of Qualigen Therapeutics Inc. the manager owns.